Abstract:Aim: To formulate and assess the anticancer effect of the poly(lactic-co-glycolic acid) (PLGA) copolymer with the thioether groups (diethyl sulfide [Des]) and disulfide bond (cystamine containing disulfide [Cys]), which encapsulated the anticancer drug paclitaxel (PTX) and triggered PTX release in cancer cell H2O2-rich or glutathione-rich surroundings. Methods: PLGA-b-P (Des@Cys) and PLGA-b-P nanoparticles loaded with PTX were prepared and characterized in vitro. The delivery ability of the PLGA-b-P nanoparticles and PLGA-b-P-PTX nanoparticles was assessed on a CT26 (mouse colon cancer cell line) and mouse lung cancer LLC model. Results: The nanoparticles were successfully prepared. Compared with free PTX, the formulated PLGA-b-P nanoparticles loaded with PTX exhibited greater accumulation at the tumor site in the mouse model. Conclusion: PLGA-b-P nanoparticles promote drug accumulation at tumor sites, providing an effective strategy for an intelligent, responsive drug-delivery system. Tweetable abstractThis study prepared polymer nanocarriers (PLGA-b-p-NPs) with double response to the tumor microenvironment and loaded with traditional antitumor drug paclitaxel, so that drugs can accurately reach tumor cells and be rapidly released in cells. Plain language summaryCancer is one of the diseases with the highest mortality rate in the world. Chemotherapy is the most frequently used method of cancer treatment. However, traditional chemotherapeutic drugs have the disadvantages of lack of specificity, high toxicity to the human body, lack of tumor targeting, inability to exist stably in the body, ease of clearance by the body and drug resistance to tumors, so clinical application is limited. Paclitaxel is widely used in the treatment of various cancers, and its use is limited due to the above disadvantages. The purpose of this study was to construct a nanodelivery system with dual responses to the tumor microenvironment, enabling the efficient accumulation of paclitaxel in solid tumors through the enhanced permeability and retention effect, enhancing the therapeutic effect of cancer. This study also investigated the intravenous safety of this dual-responsive nanodelivery system. It evaluated the toxic effects of drug-loaded nanoparticles on cancer cells and validated the controlled release of nanoparticles at tumor sites by in vivo imaging in mice. The authors concluded that tumor microenvironment dual-responsive nanoparticles are a novel and promising nanodelivery system as an intelligently responsive anticancer agent with great promise in future clinical trials.

A NAG-Guided Nano-Delivery System for Redox- and Ph-Triggered Intracellularly Sequential Drug Release in Cancer Cells

Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.

Programmed Co-Delivery of Platinum Nanodrugs and Gemcitabine by a Clustered Nanocarrier for Precision Chemotherapy for NSCLC Tumors.

Smart Ph/redox Dual-Responsive Nanogels for On-Demand Intracellular Anticancer Drug Release

Erythrocyte Membrane-Wrapped Ph Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy.

Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy

A Nanosized Codelivery System Based on Intracellular Stimuli-Triggered Dual-Drug Release for Multilevel Chemotherapy Amplification in Drug-Resistant Breast Cancer

Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.

Stepwise dual pH and redox-responsive cross-linked polypeptide nanoparticles for enhanced cellular uptake and effective cancer therapy.

A Sequentially Triggered Nanosystem for Precise Drug Delivery and Simultaneous Inhibition of Cancer Growth, Migration, and Invasion

Sequential Delivery of Cyclopeptide RA-V and Doxorubicin for Combination Therapy on Resistant Tumor and In Situ Monitoring of Cytochrome c Release

Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells

Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy

Sequential thermo-induced self-gelation and acid-triggered self-release process of drug-conjugated nanoparticles: A strategy for the sustained and controlled drug delivery to tumors

Programmable Co-Delivery of the Immune Checkpoint Inhibitor NLG919 and Chemotherapeutic Doxorubicin Via a Redox-Responsive Immunostimulatory Polymeric Prodrug Carrier

Preparation and evaluation of paclitaxel-loaded reactive oxygen species and glutathione redox-responsive poly(lactic-co-glycolic acid) nanoparticles for controlled release in tumor cells

Mitochondria-Targeting Polymer Micelles in Stepwise Response Releasing Gemcitabine and Destroying the Mitochondria and Nucleus for Combined Antitumor Chemotherapy

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine

Dual-Responsive Core-Crosslinked Polyphosphoester-Based Nanoparticles for Ph/Redox-Triggered Anticancer Drug Delivery

Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy

NGR-modified Ph-Sensitive Liposomes for Controlled Release and Tumor Target Delivery of Docetaxel.